+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ranibizumab"

Ranibizumab Market - Global Forecast 2025-2030 - Product Thumbnail Image

Ranibizumab Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 193 Pages
  • Global
From
Ranibizumab Market Report 2025 - Product Thumbnail Image

Ranibizumab Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
From
From
Optical Disorders Drugs Market - Global Forecast 2025-2030 - Product Thumbnail Image

Optical Disorders Drugs Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 199 Pages
  • Global
From
Geographic Atrophy Market Report 2025 - Product Thumbnail Image

Geographic Atrophy Market Report 2025

  • Report
  • May 2025
  • 175 Pages
  • Global
From
From
From
From
Age-Related Macular Degeneration (AMD) - Pipeline Insight, 2025 - Product Thumbnail Image

Age-Related Macular Degeneration (AMD) - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 280 Pages
  • Global
From
Proliferative Diabetic Retinopathy - Pipeline Insight, 2025 - Product Thumbnail Image

Proliferative Diabetic Retinopathy - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Retinopathy Treatment - Global Strategic Business Report - Product Thumbnail Image

Diabetic Retinopathy Treatment - Global Strategic Business Report

  • Report
  • September 2025
  • 273 Pages
  • Global
From
From
Wet Age-Related Macular Degeneration (Wet-AMD)- Pipeline Insight, 2025 - Product Thumbnail Image

Wet Age-Related Macular Degeneration (Wet-AMD)- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
Central Retinal Vein Occlusion - Pipeline Insight, 2025 - Product Thumbnail Image

Central Retinal Vein Occlusion - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Loading Indicator

Ranibizumab is a monoclonal antibody used to treat optical disorders such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). It is administered as an intravitreal injection, and works by inhibiting the activity of vascular endothelial growth factor (VEGF), which is responsible for the growth of abnormal blood vessels in the eye. Ranibizumab is the first anti-VEGF drug approved by the US Food and Drug Administration (FDA) for the treatment of wet AMD, and is now widely used in the treatment of other optical disorders. Ranibizumab is available in both branded and generic forms, and is marketed by a number of pharmaceutical companies, including Novartis, Regeneron, Genentech, and Allergan. Show Less Read more